QUEST DIAGNOSTICS INC（DGX）の決算・業績分析
QUEST DIAGNOSTICS INCの2025年有価証券報告書をAI分析。売上高$11.0B(+11.8%)。営業利益$1.6B。Health Care。
目次
QUEST DIAGNOSTICS INCの2025年度 業績サマリー
QUEST DIAGNOSTICS INC（証券コード: DGX）の2025年度決算・業績分析。売上高は$11.0B（前年比+11.8%）。営業利益は$1.6B（前年比+15.6%）。純利益は$992M（前年比+13.9%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
QUEST DIAGNOSTICS INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue declined 8.4% YoY to $9.9B (XBRL), driven by industry-wide pressures in diagnostic services.
- Net income fell 52.6% YoY to $946M (XBRL), reflecting significant margin compression despite stable operating margins (14.4%).
- The company returned $1.7B to shareholders via dividends ($305M) and buybacks ($1.4B) (XBRL).
- Net debt remained elevated at $3.7B (2.0x EBITDA) (XBRL), despite $1.3B in free cash flow.
QUEST DIAGNOSTICS INCの売上高変化の要因
- •Total revenue declined 8.4% YoY to $9.9B (XBRL), down from $10.8B in FY2023. No segment-specific revenue data is available in the provided XBRL or 10-K (XBRL). The 5-year revenue CAGR of 4.2% (XBRL) contrasts with the FY2024 decline, suggesting industry-specific headwinds may have accelerated in the most recent period.
QUEST DIAGNOSTICS INCの営業利益変化の要因
- •Operating income fell 40.0% YoY to $1.4B (XBRL), while net income dropped 52.6% YoY to $946M (XBRL). Operating margin remained stable at 14.4% (XBRL), but net margin declined to 9.6% (XBRL). Gross profit and gross margin data are not available (XBRL). EBITDA grew 18.9% YoY to $1.9B (XBRL), indicating improved efficiency in non-operating areas.
QUEST DIAGNOSTICS INCの事業リスクと対応
Evolving U.S. healthcare system with value-based reimbursement and declining demand for diagnostic services (10-K).
Intense competition from hospital-affiliated labs and new entrants (10-K).
Pressure from government payers (Medicare/Medicaid) to reduce reimbursement rates (10-K).
Technological disruption from AI, digital pathology, and point-of-care testing (10-K).
Hospital consolidation and ACOs strengthening competitive positions of affiliated labs (10-K).
QUEST DIAGNOSTICS INCの今後の見通し・業績予想
QUEST DIAGNOSTICS INCの事業内容
Quest Diagnostics Inc (DGX) provides diagnostic testing services to physicians, hospitals, patients, and healthcare entities through laboratory testing, consumer-initiated services, and data-powered IT solutions (10-K). The company leverages a comprehensive test menu, AI/automation technologies, and the Quest Management System as key competitive advantages (10-K). Key customers include physicians (serving ~50% annually), hospitals, health plans, and pharmaceutical companies (10-K). No significant customer concentration is reported (10-K).
QUEST DIAGNOSTICS INCのAI業績分析レポート（2024年度）
Quest Diagnostics Inc (DGX) FY2024 Annual Report Analysis
Highlights
Business Overview
Quest Diagnostics provides diagnostic insights through laboratory testing to improve health outcomes (10-K). The company generates revenue from net revenues ($9.9B in FY2024) (XBRL) by serving physicians, hospitals, patients, and healthcare entities. Key competitive advantages include a comprehensive test menu, AI/automation technologies, and the Quest Management System (10-K). No significant customer concentration is reported (10-K).
Revenue Analysis
Total revenue declined 8.4% YoY to $9.9B (XBRL), down from $10.8B in FY2023. The 5-year revenue CAGR of 4.2% (XBRL) contrasts with the FY2024 decline, suggesting industry-specific headwinds may have accelerated. Segment-specific revenue data is not available in the provided XBRL or 10-K (XBRL).
Profitability Analysis
Operating income fell 40.0% YoY to $1.4B (XBRL), while net income dropped 52.6% YoY to $946M (XBRL). Operating margin remained stable at 14.4% (XBRL), but net margin declined to 9.6% (XBRL). EBITDA grew 18.9% YoY to $1.9B (XBRL), indicating improved efficiency in non-operating areas. Gross profit and gross margin data are not available (XBRL).
Balance Sheet Analysis
Total assets increased to $14.0B in FY2024 (XBRL), up from $12.8B in FY2023. Long-term debt rose to $4.4B (XBRL), with net debt at $3.7B (2.0x EBITDA) (XBRL). Equity increased to $6.3B (XBRL) from $5.9B in FY2023. Current ratio of 1.31x (XBRL) suggests moderate liquidity, while equity ratio of 45.0% (XBRL) indicates balanced capital structure.
Cash Flow Analysis
Operating cash flow totaled $1.7B (XBRL), exceeding net income of $946M (XBRL). Free cash flow was $1.3B (XBRL), calculated as operating cash flow ($1.7B) minus CapEx ($404M) (XBRL). Capital expenditures amounted to $404M (XBRL), with $305M in dividends paid and $1.4B in share repurchases (XBRL).
Working Capital Analysis
Receivables days: 45 days (XBRL), Inventory days: 11 days (XBRL), Asset turnover: 0.70x (XBRL). Cash conversion cycle (CCC) data is not available (XBRL).
Risks
Outlook
No specific forward-looking guidance is provided in the 10-K text (10-K). Key trends impacting future results are not detailed in the filing (10-K).
Health Careの企業一覧
QUEST DIAGNOSTICS INCと同じ「Health Care」セクターの企業